Form 4: Jazz Pharmaceuticals Director Executes Stock Option Trade
Insider Transaction Report
Director Rick E. Winningham exercised stock options and sold a portion of the resulting shares in Jazz Pharmaceuticals.
Summary
- Director Rick E. Winningham exercised 3,415 non-qualified stock options at a strike price of $138.08 per share.
- Following the exercise, the director sold 2,741 of the acquired ordinary shares at a market price of $241.57 per share.
- The transactions resulted in a net increase of 674 shares held directly by the director, bringing the total beneficial ownership to 9,567 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine personal financial transaction by a director rather than a material change in company operations.
Positives
- The director maintains a significant equity stake of 9,567 shares in the company.
- The transaction reflects the exercise of long-held options granted in 2016, demonstrating long-term alignment with the company.
Negatives
- The director sold a portion of the shares immediately upon exercise, which may be viewed as a liquidity event rather than a long-term accumulation.
Risks
- None identified; this is a routine disclosure of director equity transactions.
Future Outlook
No forward-looking guidance or strategic outlook was provided in this regulatory filing.
Industry Context
StockSavvy.ai notes that director equity transactions are standard corporate governance disclosures and generally reflect individual financial planning rather than shifts in company strategy or industry positioning.
Comparison to Industry Standards
- The transaction follows standard SEC reporting requirements for corporate insiders.
- The exercise and sale pattern is consistent with typical executive compensation and liquidity management practices observed in the biopharmaceutical sector.
Stakeholder Impact
- Minimal impact on shareholders as the transaction size is relatively small compared to the total outstanding shares of the company.
Next Steps
- No future actions or milestones were disclosed in this filing.
Key Dates
| Date | Description |
|---|---|
| 08/11/2016 | Original grant date of the stock options. |
| 08/01/2017 | Date the stock options became fully vested. |
| 05/22/2026 | Date of the option exercise and subsequent share sale. |
| 05/27/2026 | Date the Form 4 was signed and filed. |
Keywords
Jazz Pharmaceuticals, JAZZ, Insider Trading, Form 4, Stock Options, Director Transaction
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.